114 related articles for article (PubMed ID: 37356120)
1. Heat shock protein 90 C-terminal inhibitor PNSA promotes anticancer immunology of CD8
Zhang A; Li M; Wang Y; Xiong Y; Zhu T; Qi X; Li J
Int Immunopharmacol; 2023 Aug; 121():110471. PubMed ID: 37356120
[TBL] [Abstract][Full Text] [Related]
2. PNSA, a Novel C-Terminal Inhibitor of HSP90, Reverses Epithelial-Mesenchymal Transition and Suppresses Metastasis of Breast Cancer Cells In Vitro.
Zhang A; Qi X; Du F; Zhang G; Li D; Li J
Mar Drugs; 2021 Feb; 19(2):. PubMed ID: 33672529
[TBL] [Abstract][Full Text] [Related]
3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
4. Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites.
Dai J; Zhu M; Qi X; Wang Y; Li H; Tang S; Wang Q; Chen A; Liu M; Gu Q; Li D; Li J
Biochem Pharmacol; 2020 Dec; 182():114218. PubMed ID: 32949584
[TBL] [Abstract][Full Text] [Related]
5. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
6. CD3+CD56+CD8+ cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients.
Akagi J; Takai E; Tamori Y; Ogawa M
Int J Oncol; 2001 Sep; 19(3):561-6. PubMed ID: 11494036
[TBL] [Abstract][Full Text] [Related]
7. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
Front Immunol; 2020; 11():1885. PubMed ID: 33042110
[TBL] [Abstract][Full Text] [Related]
8. Exosomes Derived From T Regulatory Cells Suppress CD8+ Cytotoxic T Lymphocyte Proliferation and Prolong Liver Allograft Survival.
Chen L; Huang H; Zhang W; Ding F; Fan Z; Zeng Z
Med Sci Monit; 2019 Jul; 25():4877-4884. PubMed ID: 31258152
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
10. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
11. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
12. Stromal Cell PD-L1 Inhibits CD8
O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.
Kawabe M; Mandic M; Taylor JL; Vasquez CA; Wesa AK; Neckers LM; Storkus WJ
Cancer Res; 2009 Sep; 69(17):6995-7003. PubMed ID: 19690146
[TBL] [Abstract][Full Text] [Related]
14. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
15. [Immunological monitoring of the efficacy of extracorporeal photopheresis for prevention of kidney transplant rejection].
Faenko AP; Chuksina YY; Zulkarnayev AB; Fedulkina VA; Vatazin AV; Kantaria RO
Urologiia; 2020 Sep; (4):73-78. PubMed ID: 32897018
[TBL] [Abstract][Full Text] [Related]
16. Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms.
Hu H; Zhao J; Yuan J; Zhang M
BMC Cancer; 2023 Mar; 23(1):287. PubMed ID: 36991376
[TBL] [Abstract][Full Text] [Related]
17. Frequencies of PD-1- and PD-L1- positive T CD3
Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
[TBL] [Abstract][Full Text] [Related]
18. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.
Nitcheu-Tefit J; Dai MS; Critchley-Thorne RJ; Ramirez-Jimenez F; Xu M; Conchon S; Ferry N; Stauss HJ; Vassaux G
J Immunol; 2007 Aug; 179(3):1532-41. PubMed ID: 17641019
[TBL] [Abstract][Full Text] [Related]
19. Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.
Kim H; Kwon HJ; Han YB; Park SY; Kim ES; Kim SH; Kim YJ; Lee JS; Chung JH
Mod Pathol; 2019 Mar; 32(3):367-375. PubMed ID: 30297881
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
